Won Ki Kang

1993–2025 年に発表

別表記
Won-Ki Kang
99
論文数
20,264
被引用数
70
h 指数
97
i10 指数

被引用数

Won Ki Kang の年別被引用数1994 年: 被引用 1 件1997 年: 被引用 1 件1998 年: 被引用 2 件1999 年: 被引用 7 件2000 年: 被引用 12 件2001 年: 被引用 7 件2002 年: 被引用 14 件2003 年: 被引用 14 件2004 年: 被引用 24 件2005 年: 被引用 29 件2006 年: 被引用 39 件2007 年: 被引用 33 件2008 年: 被引用 53 件2009 年: 被引用 39 件2010 年: 被引用 48 件2011 年: 被引用 47 件2012 年: 被引用 54 件2013 年: 被引用 75 件2014 年: 被引用 106 件2015 年: 被引用 120 件2016 年: 被引用 110 件2017 年: 被引用 139 件2018 年: 被引用 204 件2019 年: 被引用 812 件2020 年: 被引用 1,030 件2021 年: 被引用 978 件2022 年: 被引用 839 件2023 年: 被引用 650 件2024 年: 被引用 917 件2025 年: 被引用 480 件2026 年: 被引用 18 件1995〜1996 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図中国: 引用元論文 1,865 件、この内訳の 23.7%アメリカ合衆国: 引用元論文 1,380 件、この内訳の 17.6%日本: 引用元論文 639 件、この内訳の 8.1%韓国: 引用元論文 518 件、この内訳の 6.6%イタリア: 引用元論文 383 件、この内訳の 4.9%イギリス: 引用元論文 371 件、この内訳の 4.7%ドイツ: 引用元論文 317 件、この内訳の 4%フランス: 引用元論文 194 件、この内訳の 2.5%スペイン: 引用元論文 178 件、この内訳の 2.3%オランダ: 引用元論文 158 件、この内訳の 2%カナダ: 引用元論文 156 件、この内訳の 2%シンガポール: 引用元論文 112 件、この内訳の 1.4%
0%23.7%その他 20.2%

分野

  • Medicine69.9%
  • Biochemistry, Genetics and Molecular Biology23.1%
  • Immunology and Microbiology3.9%
  • Neuroscience1.2%
  • Computer Science0.5%
  • Engineering0.4%
  • その他1%

トピック

  • Gastric Cancer Management and Outcomes9.2%
  • Cancer Immunotherapy and Biomarkers9%
  • Ferroptosis and cancer prognosis3%
  • Cancer Genomics and Diagnostics2.8%
  • Cholangiocarcinoma and Gallbladder Cancer Studies2.8%
  • Gastrointestinal Tumor Research and Treatment2.8%
  • その他70.4%

共著者

全論文

検索で開く
  1. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2018 被引用: 1,717

  2. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christoph Reinhard, Andrey Loboda, Sung Kim, Amit Aggarwal, Sung Kim, Amit Aggarwal - Nature Medicine 2015 被引用: 2,244

  3. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2017 被引用: 2,279

  4. Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability–High Gastric Cancer

    著者: , , , , , , , , , , , , , , , , - Cancer Discovery 2021 被引用: 241

  5. Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 被引用: 474

  6. Early Tumor–Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer

    著者: , , , , , , , , , , , , , , , - Cancer Discovery 2021 被引用: 175

  7. Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project

    著者: , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2017 被引用: 479

  8. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeeyun Lee, Won Ki Kang, Sung Hoon Kim, Sung Hoon Noh, Gordon B. Mills, Seon‐Young Kim, Jaffer A. Ajani, Ju‐Seog Lee, Seon‐Young Kim, Jaffer A. Ajani, Ju‐Seog Lee, Ju‐Seog Lee - Nature Communications 2018 被引用: 464

  9. Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer

    著者: , , , , , , , , , - Translational Cancer Research 2020 被引用: 93

  10. Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jung Yong Hong, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, AmirAli Talasaz, Simon J. Hollingsworth, Kyoung‐Mee Kim, Won Ki Kang - Cancer Discovery 2019 被引用: 234

  11. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer

    著者: , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2022 被引用: 89

  12. Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer

    著者: , , , , , , , , , , - Science Advances 2023 被引用: 43

  13. Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia

    著者: , , , , , , , , , , , - Journal of Clinical Oncology 2013 被引用: 507

  14. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆

    著者: , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2020 被引用: 286

  15. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Gastric Cancer 2019 被引用: 231

  16. FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival

    著者: , , , , , , , , , , , , - Modern Pathology 2016 被引用: 114

  17. Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer

    著者: , , , , , , , , , , , , , , , , , , - Cancer Discovery 2024 被引用: 51

  18. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Gastric Cancer 2021 被引用: 123

  19. Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer

    著者: , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2021 被引用: 79

  20. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer

    著者: , , , , , , , , , , , , , , , - Molecular Therapy 2015 被引用: 180

  21. Simvastatin plus capecitabine–cisplatin versus placebo plus capecitabine–cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study

    著者: , , , , , , , , , , , - European Journal of Cancer 2014 被引用: 113

  22. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial

    著者: , , , , , , , , , , , , , , - Annals of Oncology 2009 被引用: 777

  23. Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial

    著者: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2011 被引用: 812

  24. Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone

    著者: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2012 被引用: 672